EA
FBIO icon

Emerald Acquisition’s Fortress Biotech FBIO Stock Holding History

Emerald Acquisition’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,350
Closed -$54K – 3000
2016
Q2 		$54K Buy
+1,350
New +$62.9K ﹤0.01% 2909

Other funds holding FBIO

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Emerald Acquisition's FBIO Position: Q3 2016 in Review

Emerald Acquisition sold out of Fortress Biotech (FBIO) in Q3 2016, closing a stake of 1,350 shares — an estimated $54K sold.

Emerald Acquisition first reported a position in FBIO in Q2 2016 and held it in 1 quarter. The position peaked at $54K in Q2 2016. 50 funds tracked by Wall St. Rank hold FBIO as of Q3 2016.

  • Emerald Acquisition reported no remaining Fortress Biotech position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 1,350 Fortress Biotech shares in Q3 2016, an estimated $54K.
  • Emerald Acquisition first reported a position in Fortress Biotech in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Fortress Biotech position peaked at $54K in Q2 2016.
  • 50 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.